12-week clinical effects of erythropoietin espogen™ in end stage renal patients undergoing hemodialysis

Journal of the Medical Association of Thailand

Volumn 90, Issue 4, 2007, Pages 636-642

  Thitiarchakul, Supachai ^a,b   Tasanarong, Adis ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Anemia; End stage renal failure; Erythropoietin; Espogen ; Hemodialysis

Indexed keywords

CYANOCOBALAMIN; ESPOGEN; FERRITIN; FOLIC ACID; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MALE; MEAN ARTERIAL PRESSURE; RASH; SIDE EFFECT; TREATMENT RESPONSE;

ANEMIA; BLOOD PRESSURE; EPOETIN ALFA; FEMALE; FERRITINS; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 34247377343     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Macdougall IC. Erythropoietin and renal failure. Curr Hematol Rep 2003; 2: 459-64.
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
3. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with endstage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.
4. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur J Clin Pharmacol 1996; 50: 171-7.
5. National Kidney Foundation. IV. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1): S182-S238.
6. Trakarnvanich T, Thitiarcharkul S. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients. J Med Assoc Thai 2004; 87: 1041-7.
7. Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 2005; 68: 1432-8.
8. National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47(5 Suppl 3): S81-5.
9. Ho JS, Chung WK, Ahn C, Huh WS, Oh HY, Park JS. Clinical effect of recombinant erythropoietin (rhEPO, ESPOGEN TM) in anemia of chronic renal failure patients on dialysis. Korean J Nephrol 2000; 19: 312-9.
10. Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 1992; 304: 225-6.
11. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig 1994; 72: S36-S43.
12. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-6.
13. Yeo HM, Kim DJ, Choi SY, Do YS, Jang EH, Baek HJ, et al. Effect of high dose (10000 IU) epoietin alfa (espogen) therapy in continuous ambulatory peritoneal dialysis (CAPD) patients. Korean J Nephrol 2005; 24: 1-7.